Prevalence of children born small for gestational age with short stature who qualify for growth hormone treatment

BACKGROUND: Recombinant human growth hormone (rhGH) is approved in Europe as a treatment for short children born small for gestational age (SGA) since 2003. However, no study evaluated the prevalence of SGA children with short stature who qualify for rhGH in Europe so far. This study aimed to invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamaro, Gianluca, Pizzul, Mariagrazia, Gaeta, Giuliana, Servello, Raffaella, Trevisan, Marina, Böhm, Patricia, Materassi, Paola Manera Ada, Macaluso, Anna, Valentini, Denis, Pellegrin, Maria Chiara, Barbi, Egidio, Tornese, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015030/
https://www.ncbi.nlm.nih.gov/pubmed/33794966
http://dx.doi.org/10.1186/s13052-021-01026-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8015030/
https://www.ncbi.nlm.nih.gov/pubmed/33794966
http://dx.doi.org/10.1186/s13052-021-01026-3

Ejemplares similares